7 questions about side effects.
Contact the prescriber for persistent or severe symptoms, inability to keep fluids down, or abdominal pain. Dose changes, pauses and switching should be clinician-directed under the exact product label.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
“Peptide” is a chemical class, not a safety rating. An approved medicine has product-specific evidence and labeling; a compounded preparation is not FDA-approved; an investigational or research-use product has different and often much greater uncertainty.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
No. Peptides and steroids are different chemical classes, but that does not make peptides inherently safe or legal for a particular use.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
Do not assume safety in pregnancy or breastfeeding. Check the exact medicine’s label and contact the prescriber. Many products have insufficient data, restrictions, or recommendations to stop before pregnancy.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
There is no universal peptide side-effect list or frequency. Adverse effects depend on the exact active ingredient, formulation, dose, route, population and product quality.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
No adequate human evidence establishes BPC-157 as a treatment for GLP-1 nausea. It is not an FDA-approved rescue medicine and adds product-quality and interaction uncertainty.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
A small local reaction can occur with some labeled injections, but redness, warmth, swelling, drainage, worsening pain, fever, hives or breathing symptoms need prompt clinical assessment. Follow the exact product label.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
← All FAQ topics | Browse all peptides
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify